Ocular Therapeutix (NASDAQ:OCUL) Sets New 1-Year Low - What's Next?

Key Points

• Ocular Therapeutix shares hit a new 52-week low, trading as low as $6.00 on Friday, below the prior close of $6.28.
• The company’s latest quarter fell short of expectations: it reported an adjusted loss of $0.42 per share versus the $0.36 consensus loss, while revenue of $12.87 million missed estimates and declined 11.5% year over year.
• Analyst sentiment remains broadly positive, with a “Moderate Buy” consensus and an average price target of $23.83; investors are also weighing Phase 3 wet AMD results against valuation concerns and projected losses.

Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report) reached a new 52-week low on Friday. The stock traded as low as $6.00 and last traded at $6.0540, with a volume of 541,312 shares traded. The stock had previously closed at $6.28.

Trending Headlines about Ocular Therapeutix

These are some of the OCUL headlines that stood out recently:

• Positive Sentiment: Ocular Therapeutix’s Phase 3 wet AMD success is a potential clinical catalyst and may support optimism about its development prospects. The articles also note that investors continue to debate how much of that opportunity is reflected in the company’s valuation. How Investors Are Reacting To Ocular Therapeutix (OCUL) Phase 3 Wet AMD Success Ocular Therapeutix (OCUL) On Phase 3 AMD Win And Why The Valuation Debate Persists
• Positive Sentiment: HC Wainwright raised its price target and retained a Buy rating, while RBC Capital also kept its Buy rating. These recommendations offer a favorable analyst view, though the provided reports do not specify RBC’s target or the details of HC Wainwright’s increase. Ocular Therapeutix Stock Gets Price Target Increase from HC Wainwright RBC Capital Keeps Their Buy Rating on Ocular Therapeutix
• Negative Sentiment: HC Wainwright cut its projected losses across fiscal 2026 and 2027 and several upcoming quarters, including lowering its FY2027 EPS forecast to ($1.87) from ($1.54). The revisions suggest higher expected losses and could weigh on sentiment, despite the firm’s continued Buy rating and $28 target. Ocular Therapeutix analyst estimates

Analysts Set New Price Targets

Several equities research analysts have issued reports on OCUL shares. Chardan Capital reiterated a "buy" rating and set a $23.00 target price on shares of Ocular Therapeutix in a research report on Friday, October 2nd. Weiss Ratings reissued a "sell (d-)" rating on shares of Ocular Therapeutix in a report on Thursday, October 15th. UBS Group initiated coverage on shares of Ocular Therapeutix in a report on Sunday, October 11th. They issued a "buy" rating and a $14.00 price target on the stock. HC Wainwright raised their price objective on shares of Ocular Therapeutix from $25.00 to $28.00 and gave the company a "buy" rating in a research report on Tuesday. Finally, Wall Street Zen raised shares of Ocular Therapeutix from a "sell" rating to a "hold" rating in a report on Saturday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Ocular Therapeutix has an average rating of "Moderate Buy" and a consensus price target of $23.83.

Ocular Therapeutix Price Performance

The company has a debt-to-equity ratio of 0.17, a quick ratio of 13.03 and a current ratio of 9.12. The stock has a market capitalization of $1.37 billion, a P/E ratio of -4.27 and a beta of 1.22. The firm has a 50-day moving average price of $8.08 and a 200 day moving average price of $8.93.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last released its earnings results on Monday, November 9th. The biopharmaceutical company reported ($0.42) earnings per share for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.06). The firm had revenue of $12.87 million during the quarter, compared to the consensus estimate of $14.27 million. Ocular Therapeutix had a negative return on equity of 59.95% and a negative net margin of 648.64%. The business's quarterly revenue was down 11.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.38) EPS. On average, analysts expect that Ocular Therapeutix, Inc. will post -1.58 EPS for the current year.

Insider Activity

In related news, insider Todd Anderman sold 11,984 shares of the stock in a transaction on Thursday, October 8th. The shares were sold at an average price of $7.29, for a total transaction of $87,363.36. Following the transaction, the insider owned 140,484 shares of the company's stock, valued at approximately $1,024,128.36. This trade represents a 7.86% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Namrata Saroj sold 35,370 shares of Ocular Therapeutix stock in a transaction on Thursday, November 5th. The stock was sold at an average price of $6.55, for a total transaction of $231,673.50. Following the completion of the transaction, the insider owned 220,522 shares in the company, valued at approximately $1,444,419.10. The trade was a 13.82% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders sold 98,090 shares of company stock valued at $787,920. Insiders own 3.10% of the company's stock.

Institutional Trading of Ocular Therapeutix

Several institutional investors have recently added to or reduced their stakes in the business. Commonwealth Equity Services LLC boosted its holdings in Ocular Therapeutix by 8.1% during the 3rd quarter. Commonwealth Equity Services LLC now owns 20,992 shares of the biopharmaceutical company's stock valued at $161,000 after acquiring an additional 1,575 shares during the period. Principal Financial Group Inc. boosted its stake in shares of Ocular Therapeutix by 24.1% during the first quarter. Principal Financial Group Inc. now owns 13,623 shares of the biopharmaceutical company's stock valued at $115,000 after purchasing an additional 2,642 shares during the period. NewEdge Advisors LLC grew its holdings in shares of Ocular Therapeutix by 21.7% in the second quarter. NewEdge Advisors LLC now owns 16,725 shares of the biopharmaceutical company's stock worth $164,000 after purchasing an additional 2,979 shares during the last quarter. Raiffeisen Bank International AG grew its holdings in shares of Ocular Therapeutix by 5.3% in the second quarter. Raiffeisen Bank International AG now owns 100,000 shares of the biopharmaceutical company's stock worth $990,000 after purchasing an additional 5,000 shares during the last quarter. Finally, Integrated Wealth Concepts LLC bought a new position in shares of Ocular Therapeutix in the second quarter worth approximately $51,000. 59.21% of the stock is currently owned by hedge funds and other institutional investors.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for eye diseases and conditions. Based in Bedford, Massachusetts, the company uses its proprietary hydrogel-based technology to deliver medicines to the eye over time. Its marketed product, DEXTENZA, is a corticosteroid insert placed in the tear duct by an eye-care professional to treat inflammation and pain following ophthalmic surgery. Ocular Therapeutix also develops investigational therapies for retinal diseases and other eye conditions, including treatments designed for sustained drug delivery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.